<?xml version="1.0" encoding="UTF-8"?>
<rootTag>
<Award>
<AwardTitle>SBIR Phase I:  BioSense AMD - A Point-of-Care Device for Monitoring Airway Inflammation</AwardTitle>
<AGENCY>NSF</AGENCY>
<AwardEffectiveDate>05/01/2020</AwardEffectiveDate>
<AwardExpirationDate>02/28/2021</AwardExpirationDate>
<AwardTotalIntnAmount>224808.00</AwardTotalIntnAmount>
<AwardAmount>224808</AwardAmount>
<AwardInstrument>
<Value>Standard Grant</Value>
</AwardInstrument>
<Organization>
<Code>07070000</Code>
<Directorate>
<Abbreviation>ENG</Abbreviation>
<LongName>Directorate For Engineering</LongName>
</Directorate>
<Division>
<Abbreviation>IIP</Abbreviation>
<LongName>Div Of Industrial Innovation &amp; Partnersh</LongName>
</Division>
</Organization>
<ProgramOfficer>
<SignBlockName>Henry Ahn</SignBlockName>
<PO_EMAI>hahn@nsf.gov</PO_EMAI>
<PO_PHON>7032927069</PO_PHON>
</ProgramOfficer>
<AbstractNarration>This Small Business Innovation Research (SBIR) Phase I project aims to develop a point-of-care biomedical device for the rapid and quantitative measurement of airway inflammation.  Currently, methods to measure airway inflammation and disease control are difficult.  Recent innovation in breath analysis has provided opportunity to better understand airway disease.  However, the reach of these innovations has been limited due to cost and availability. Chronic lower respiratory diseases including asthma, chronic obstructive pulmonary disease (COPD), emphysema, and pulmonary hypertension are the fourth leading cause of death in the United States and a leading cause of death worldwide across all countries and income levels. There is an urgent need for methods to better monitor and manage these chronic lower respiratory diseases to improve survival and patientsâ€™ quality of life. Using an advanced chemical system, the proposed technology will measure a biomarker of inflammation in exhaled breath condensate (EBC).  Success of this project will deeply impact fundamental pulmonary research and create broad societal value by improving health and reducing burdens on the healthcare system. This will be particularly valuable to underserved urban communities where poor air quality leads to increased severity of respiratory diseases. This product also has significant commercial potential, with the ability to reduce costs and streamline treatment in an industry valued over $100 B annually.&lt;br/&gt;&lt;br/&gt;This Small Business Innovation Research (SBIR) Phase I project aims to develop and implement an advanced proprietary automated chemiluminescent reagent mixing and detector system for instantaneous measurement of airway inflammation by real-time breath analysis. Hydrogen peroxide reports on airway inflammation, which is a critical factor in respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD), but is difficult to accurately measure at the point-of-care. The current methods of choice include highly invasive bronchoalveolar lavage (BAL), time-consuming and costly laboratory hydrogen peroxide assays, or fractional exhaled nitric oxide (FeNO), which provides an incomplete picture of airway inflammation. This project will fill this analysis gap and provide a valuable solution to monitoring airway inflammation in patients at the point-of-care. The proposed aims for developing a system to measure exhaled hydrogen peroxide in Phase I will include: a cartridge-based reagent delivery and mixing designed to optimize limit of detection and reproducibility; a robust and compact reader equipped with optimized photon detection technology and built-in vortex mixer; and careful analysis of sensitivity and selectivity for hydrogen peroxide versus potentially interfering analytes.&lt;br/&gt;&lt;br/&gt;This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.</AbstractNarration>
<MinAmdLetterDate>04/27/2020</MinAmdLetterDate>
<MaxAmdLetterDate>04/27/2020</MaxAmdLetterDate>
<ARRAAmount/>
<TRAN_TYPE>Grant</TRAN_TYPE>
<CFDA_NUM>47.041</CFDA_NUM>
<NSF_PAR_USE_FLAG>1</NSF_PAR_USE_FLAG>
<FUND_AGCY_CODE>4900</FUND_AGCY_CODE>
<AWDG_AGCY_CODE>4900</AWDG_AGCY_CODE>
<AwardID>2015081</AwardID>
<Investigator>
<FirstName>Miguel</FirstName>
<LastName>Quimbar</LastName>
<PI_MID_INIT>E</PI_MID_INIT>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Miguel E Quimbar</PI_FULL_NAME>
<EmailAddress>mequimbar@biolumsciences.com</EmailAddress>
<PI_PHON>2106189469</PI_PHON>
<NSF_ID>000806848</NSF_ID>
<StartDate>04/27/2020</StartDate>
<EndDate/>
<RoleCode>Principal Investigator</RoleCode>
</Investigator>
<Institution>
<Name>BioLum Sciences, LLC</Name>
<CityName>San Diego</CityName>
<ZipCode>921211126</ZipCode>
<PhoneNumber>7209853131</PhoneNumber>
<StreetAddress>3210 Merryfield Row</StreetAddress>
<StreetAddress2/>
<CountryName>United States</CountryName>
<StateName>California</StateName>
<StateCode>CA</StateCode>
<CONGRESSDISTRICT>18</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_ORG>CA18</CONGRESS_DISTRICT_ORG>
<ORG_DUNS_NUM>080065785</ORG_DUNS_NUM>
<ORG_LGL_BUS_NAME>BIOLUM SCIENCES, LLC</ORG_LGL_BUS_NAME>
<ORG_PRNT_DUNS_NUM/>
</Institution>
<Performance_Institution>
<Name><![CDATA[BioLum Sciences, LLC]]></Name>
<CityName>San Francisco</CityName>
<StateCode>CA</StateCode>
<ZipCode>941582158</ZipCode>
<StreetAddress><![CDATA[455 Mission Bay Boulevard South]]></StreetAddress>
<CountryCode>US</CountryCode>
<CountryName>United States</CountryName>
<StateName>California</StateName>
<CountryFlag>1</CountryFlag>
<CONGRESSDISTRICT>12</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_PERF>CA12</CONGRESS_DISTRICT_PERF>
</Performance_Institution>
<ProgramElement>
<Code>5371</Code>
<Text>SBIR Phase I</Text>
</ProgramElement>
<ProgramReference>
<Code>8038</Code>
<Text>Biotechnology</Text>
</ProgramReference>
<Appropriation>
<Code>0120</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<FUND_OBLG>2020~224808</FUND_OBLG>
<POR>
<DRECONTENT><![CDATA[<div class="porColContainerWBG"> <div class="porContentCol"><p><strong>Project Summary</strong></p> <p>This Phase I SBIR project aimed to develop and validate key components of the BioSense Airway Monitoring Device (AMD), a point-of-care device for real-time measurement of hydrogen peroxide in exhaled breath condensate, a biomarker of airway inflammation. All critical Phase I project milestones were met and provided the required data to support the development of the final BioSense Airway Monitoring Device as the company nears commercial product sales. Chronic respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD) pose a steep societal burden and significant healthcare costs that arise from challenges associated with disease management. The BioSense AMD will empower clinicians and patients by providing an instant readout of airway inflammation, enabling early identification of exacerbations and rapid treatment optimization.</p> <p>&nbsp;</p> <p><strong>Intellectual Merit</strong></p> <p>Airway inflammation is a critical factor in respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD). Existing methods to measure airway inflammation can be highly invasive, time-consuming, and costly. During this Phase I project, BioLum developed a semi-automated cartridge-based system and integrated a detection sensor for measurement of hydrogen peroxide at the point-of-care with minimal user effort. The success of this automated test provides a firm foundation for the Phase II goals of finalizing the BioSense AMD device. The availability of this device will further impact many different fields where hydrogen peroxide is an important analyte, including the study of respiratory diseases and explosives detection. A particularly empowering and innovative application of this device is the early warning of exacerbation in asthma and chronic obstructive pulmonary disease (COPD), which could allow for early intervention and ultimately save lives. Currently, prediction of exacerbation for early intervention is urgently needed to improve patient outcomes and reduce healthcare costs. The ability to easily perform exhaled breath condensate (EBC) hydrogen peroxide measurements will enable transformative scientific and clinical studies of respiratory diseases, by providing a rapid, non-invasive readout for airway inflammation.</p> <p>&nbsp;</p> <p><strong>Broader Impacts</strong></p> <p>Chronic lower respiratory diseases including asthma, chronic obstructive pulmonary disease (COPD), emphysema, and pulmonary hypertension are the fourth leading cause of death in the United States and a leading cause of death worldwide across all countries and income levels. The success of this project will deeply impact fundamental pulmonary research and create broad societal value by improving health and reducing healthcare system burdens. This will be particularly valuable in urban communities where poor air quality disproportionately afflicts under-represented populations leading to increased severity of respiratory diseases. Additionally, respiratory diseases are challenging to manage in rural communities where monitoring is complicated by factors including poor internet availability and distance from specialist healthcare providers. BioLum's point-of-care medical device for monitoring asthma and chronic obstructive pulmonary disease (COPD) will enable rapid evaluation of drug efficacy and prediction of exacerbation, significantly improving health outcomes and quality-of-life for these patients. The BioSense AMD will improve quality of life and prevent unnecessary deaths by enabling better and more precise management of disease, ultimately providing a home-monitoring solution and a broad societal benefit to these groups.</p><br> <p>            Last Modified: 03/26/2021<br>      Modified by: Miguel&nbsp;E&nbsp;Quimbar</p> </div> <div class="porSideCol"></div> </div>]]></DRECONTENT>
<POR_COPY_TXT><![CDATA[ Project Summary  This Phase I SBIR project aimed to develop and validate key components of the BioSense Airway Monitoring Device (AMD), a point-of-care device for real-time measurement of hydrogen peroxide in exhaled breath condensate, a biomarker of airway inflammation. All critical Phase I project milestones were met and provided the required data to support the development of the final BioSense Airway Monitoring Device as the company nears commercial product sales. Chronic respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD) pose a steep societal burden and significant healthcare costs that arise from challenges associated with disease management. The BioSense AMD will empower clinicians and patients by providing an instant readout of airway inflammation, enabling early identification of exacerbations and rapid treatment optimization.     Intellectual Merit  Airway inflammation is a critical factor in respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD). Existing methods to measure airway inflammation can be highly invasive, time-consuming, and costly. During this Phase I project, BioLum developed a semi-automated cartridge-based system and integrated a detection sensor for measurement of hydrogen peroxide at the point-of-care with minimal user effort. The success of this automated test provides a firm foundation for the Phase II goals of finalizing the BioSense AMD device. The availability of this device will further impact many different fields where hydrogen peroxide is an important analyte, including the study of respiratory diseases and explosives detection. A particularly empowering and innovative application of this device is the early warning of exacerbation in asthma and chronic obstructive pulmonary disease (COPD), which could allow for early intervention and ultimately save lives. Currently, prediction of exacerbation for early intervention is urgently needed to improve patient outcomes and reduce healthcare costs. The ability to easily perform exhaled breath condensate (EBC) hydrogen peroxide measurements will enable transformative scientific and clinical studies of respiratory diseases, by providing a rapid, non-invasive readout for airway inflammation.     Broader Impacts  Chronic lower respiratory diseases including asthma, chronic obstructive pulmonary disease (COPD), emphysema, and pulmonary hypertension are the fourth leading cause of death in the United States and a leading cause of death worldwide across all countries and income levels. The success of this project will deeply impact fundamental pulmonary research and create broad societal value by improving health and reducing healthcare system burdens. This will be particularly valuable in urban communities where poor air quality disproportionately afflicts under-represented populations leading to increased severity of respiratory diseases. Additionally, respiratory diseases are challenging to manage in rural communities where monitoring is complicated by factors including poor internet availability and distance from specialist healthcare providers. BioLum's point-of-care medical device for monitoring asthma and chronic obstructive pulmonary disease (COPD) will enable rapid evaluation of drug efficacy and prediction of exacerbation, significantly improving health outcomes and quality-of-life for these patients. The BioSense AMD will improve quality of life and prevent unnecessary deaths by enabling better and more precise management of disease, ultimately providing a home-monitoring solution and a broad societal benefit to these groups.       Last Modified: 03/26/2021       Submitted by: Miguel E Quimbar]]></POR_COPY_TXT>
</POR>
</Award>
</rootTag>
